Abstract
Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have